Cho YK, Lee J, Kang YM, et al. - Researchers sought for the clinical factors associated with the therapeutic efficacy of the sodium–glucose cotransporter-2 inhibitor empagliflozin in patients with type 2 diabetes mellitus (T2DM). On analyzing the medical records of 374 T2DM patients (aged between 20 and 75 years) prescribed empagliflozin 10 mg or 25 mg for more than 90 consecutive days, they identified a better glycemic response in correlation to younger age (≤ 50 years), the highest levels of hemoglobin A1c (HbA1c) (> 9%) at baseline, an estimated glomerular filtration rate of > 90 mL/min/1.73 m², and a shorter duration of T2DM (< 10 years). A more significant reduction in body weight among patients taking empagliflozin was observed in correlation to higher BMI and lower HbA1c levels.